FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.
Read the full article on the original site.
Read Full Article